Your browser doesn't support javascript.
loading
Chronic pain and depression among primary care patients treated with buprenorphine.
Stein, Michael D; Herman, Debra S; Bailey, Genie L; Straus, John; Anderson, Bradley J; Uebelacker, Lisa A; Weisberg, Risa B.
Afiliación
  • Stein MD; Butler Hospital, Providence, Rhode Island, 345 Blackstone Boulevard, Providence, RI, 02906, USA, Michael_Stein@Brown.edu.
J Gen Intern Med ; 30(7): 935-41, 2015 Jul.
Article en En | MEDLINE | ID: mdl-25678375
ABSTRACT

BACKGROUND:

Pain and depression are each prevalent among opioid dependent patients receiving maintenance buprenorphine, but their interaction has not been studied in primary care patients.

OBJECTIVE:

We set out to examine the relationship between chronic pain, depression, and ongoing substance use, among persons maintained on buprenorphine in primary care settings.

DESIGN:

Between September 2012 and December 2013, we interviewed buprenorphine patients at three practice sites.

PARTICIPANTS:

Opioid dependent persons at two private internal medicine offices and a federally qualified health center participated in the study. MAIN

MEASURES:

Pain was measured in terms of chronicity, with chronic pain being defined as pain lasting at least 6 months; and in terms of severity, as measured by self-reported pain in the past week, measured on a 0-100 scale. We defined mild chronic pain as pain severity between 0 and 39 and lasting at least 6 months, and moderate/severe chronic pain as severity ≥ 40 and lasting at least 6 months. To assess depression, we used the Center for Epidemiologic Studies Depression (CESD) ten-item symptom scale and the two-item Patient Health Questionnaire (PHQ-2). KEY

RESULTS:

Among 328 participants, 169 reported no chronic pain, 56 reported mild chronic pain, and 103 reported moderate/severe chronic pain. Participants with moderate/severe chronic pain commonly used non-opioid pain medications (56.3%) and antidepressants (44.7%), yet also used marijuana, alcohol, or cocaine (40.8%) to help relieve pain. Mean CESD scores were 7.1 (±6.8), 8.3 (±6.0), and 13.6 (±7.6) in the no chronic, mild, and moderate/severe pain groups, respectively. Controlling for covariates, higher CESD scores were associated with a higher likelihood of moderate/severe chronic pain relative to both no chronic pain (OR = 1.09, p < 0.001) and mild chronic pain (OR = 1.06, p = 0.04).

CONCLUSION:

Many buprenorphine patients are receiving over-the-counter or prescribed pain medications, as well as antidepressants, and yet continue to have significant and disabling pain and depressive symptoms. There is a clear need to address the pain-depression nexus in novel ways.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Buprenorfina / Depresión / Dolor Crónico / Trastornos Relacionados con Opioides Tipo de estudio: Clinical_trials / Diagnostic_studies / Observational_studies / Prevalence_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged País/Región como asunto: America do norte Idioma: En Revista: J Gen Intern Med Asunto de la revista: MEDICINA INTERNA Año: 2015 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Buprenorfina / Depresión / Dolor Crónico / Trastornos Relacionados con Opioides Tipo de estudio: Clinical_trials / Diagnostic_studies / Observational_studies / Prevalence_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged País/Región como asunto: America do norte Idioma: En Revista: J Gen Intern Med Asunto de la revista: MEDICINA INTERNA Año: 2015 Tipo del documento: Article